|
Wednesday April 28, 2010
| 7.30 a.m. |
Continental Breakfast |
| |
|
| |
MEETING BREAK FOR RECREATION.
Participants are free to play golf, tennis and relax poolside. One of Four special excursions are available.
|
| |
|
| SESSION 8: |
Drug Deposition Modeling: Advancing the Art |
| |
|
| |
Sponsor: Philip Morris International
Moderator: Bo Olsson, Ph.D.
|
| |
|
| 1.30 p.m. |
Choosing 3-D Mouth-throat Dimensions: A Rational Merging of Medical Imaging and Aerodynamics.
Warren H. Finlay, Ph.D.,
University of Alberta, Edmonton, Canada. |
| |
|
| 2.00 p.m. |
Can Pediatric Throat Models and Air Flow Profiles Improve Our Dose Finding Strategy?
Herbert Wachtel, Ph.D.,
Boehringer Ingelheim, Ingelheim, Germany. |
| |
|
| 2.30 p.m. |
Dosimetry Implications of Uncertainties in Lung Architecture: Is Weibel Good Enough?
Michael J. Oldham, Ph.D.,
Altria Client Services, Richmond, VA. |
| |
|
| 3.00 p.m. |
Refreshments |
| |
|
3.30 p.m.
|
Stepping into the Trachea with Realistic Physical Models: Uncertainties in Regional Drug Deposition from Powder Inhalers.
Peter R. Byron, Ph.D.,
Virginia Commonwealth University, Richmond, VA. |
| |
|
| 4.00 p.m. |
Comparing Aerosol Size Distributions that Penetrate Mouth-throat Models under Realistic Inhalation Conditions.
Bo Olsson, Ph.D.,
AstraZeneca, Lund, Sweden. |
| |
|
4.30 p.m.
|
Beyond the Throat: Preferred Methods of Assessing Regional Distribution in the Lung.
Andrew R. Clark, Ph.D.,
Novartis, San Carlos, CA. |
| |
|
| 5.00 p.m. |
Panel Discussion |
| |
|
| 6.30 p.m. |
Cocktail Reception |
| |
|
| |
Sponsored by ‘Our Platinum & Gold Sponsors’ |
| |
|
| 7.30 p.m. |
Banquet & Dancing |
| |
|
| |
Sponsored by ‘Our Platinum & Gold Sponsors’ |
|
|
|
|
